In Wednesday’s trading session, the shares of one of the leading pharmaceutical companies in India surged by 2.5 percent day’s trade after commissioning of a new production block at its Ambernath unit in Maharashtra, India with a Capex plan of Rs. 10 Crores.
Price action
With a market capitalization of 8,714.9 Crores on Wednesday, the shares of Blue Jet Healthcare Ltd rose by 2.5 percent making a high of Rs 518.65 compared to its previous closing price of Rs 503.50.
What happened
Blue Jet Healthcare Ltd surged on Wednesday following the commissioning of a new production block at its Ambernath unit in Maharashtra. The new facility will focus on manufacturing advanced contrast media, which is essential for medical imaging.
The company has an existing capacity of 1,140.90 KL with the current utilization rate of approximately 70 percent following which the company plans to expand its production by an additional 37.6 KL over the next three months with an investment of Rs. 10 Crores approximately for expansion, which will be financed through the company’s internal accruals.
This development is part of Blue Jet Healthcare’s broader strategy to strengthen its manufacturing capabilities and meet the increasing demand for advanced contrast media in the market.
About the company
Blue Jet Healthcare Ltd specialises in the development and manufacturing of high-quality contrast media intermediaries, High intensity Sweeteners and Pharma Intermediates & APIs and other healthcare products with a focus on delivering advanced, safe and effective products to meet the growing demands of the healthcare sector.
With a strong presence in the healthcare industry, the company is committed to providing innovative solutions that support medical imaging and diagnostic processes,Through continuous research and development, along with state-of-the-art manufacturing facilities, the company aims to enhance its capabilities and expand its reach in the global market.
Financials
The company’s revenue rose by 16.23 percent from Rs 189.56 crore in Q2FY24 to Rs 220.33 crore in Q2FY25. Meanwhile, Net profit rose by 21.89 percent from Rs 47.87 crores to Rs 58.35 crore during the same period.
Key Financial ratios
Blue Jet Healthcare Ltd has an impressive Return on Equity (RoE) of 18 percent and a Return on Capital Employed (RoCE) of 24 percent and PE ratio of 50. Furthermore, the company’s debt-to-equity ratio is 0.
Shareholding Pattern
Blue Jet Healthcare Ltd. has a well-diversified shareholding structure. As of September 2024, The promoters hold 86 percent, while Foreign Institutional Investors (FIIs) own 2.18 percent and Domestic Institutional Investors (DIIs) hold 1.74 percent. The remaining 10.07 percent is owned by the public, It reflects a balanced mix of promoter control and investor confidence from both institutional and retail shareholders.
Stock Performance
The stock has provided returns of about 48.17 percent over the last year, along with a 31 percent gain in the past six months of 2024, it has continued to perform strongly.
Written by Sridhar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
